Bedaquiline, a new antituberculosis drug, has already been used in> 50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this …

Introduction Therapeutic drug monitoring (TDM) has been recommended for treatment
optimization in tuberculosis (TB) but is only is used in certain countries eg USA, Germany …

Background Prospective studies correlating pharmacokinetic/pharmacodynamic (PK/PD)
indices to clinical responses are urgently needed. This study aimed to find clinically relevant …

New non-sputum biomarker tests for active tuberculosis (TB) diagnostics are of the highest
priority for global TB control. We performed in-depth proteomic analysis using the 4,000-plex …

Introduction Contrasting findings have been published regarding the effect of human
immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). Objectives …

Background Therapeutic drug monitoring (TDM) is a tool to personalize and optimize dosing
by measuring the drug concentration and subsequently adjusting the dose to reach a target …

Tuberculosis (TB) is a leading cause of infectious death. Nontuberculous mycobacteria
(NTM) cause a wide variety of difficult-to-treat infections in various human hosts. Therapeutic …

Objectives No population pharmacokinetics (PK) model of isoniazid (INH) has been reported
for the Indonesian population with tuberculosis (TB). Therefore, we aimed to develop a …

Abstract According to the World Health Organization (WHO), tuberculosis is the leading
cause of death attributed to a single microbial pathogen worldwide. In addition to the large …

Tuberculosis (TB) is considered as one of the most serious threats to public health in many
parts of the world. The threat is even more severe in the developing countries where there is …